Pulse Brain · Growing Health Evidence Index
Peer-reviewed

<i>Escherichia coli</i> –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer

Anne‐Gaëlle Goubet, Leonardo Lordello, Carolina Alves Costa Silva, Isabelle Peguillet, Marianne Gazzano, Maxime Descartes Mbogning Fonkou, Cassandra Thélémaque, C. Lebâcle, Constance Thibault, François Audenet, G. Pignot, Gwénaëlle Gravis, Carole Hélissey, Luca Campedel, Morgan Rouprêt, Évanguelos Xylinas, Idir Ouzaïd, Agathe Dubuisson, Marine Mazzenga, Caroline Flament, Pierre Ly, Virginie Marty, Nicolas Signolle, Allan Sauvat, Thomas Sbarrato, Mounia Filahi, Caroline Davin, Gabriel Haddad, Jacques Bou Khalil, Camille Blériot, François‐Xavier Danlos, Garett Dunsmore, Kevin Mulder, Aymeric Silvin, Thibault Raoult, Baptiste Archambaud, Shaima Belhechmi, Ivo G. Boneca, Nadège Cayet, Maryse Moya‐Nilges, Adeline Mallet, Romain Daillère, Étienne Rouleau, C. Radulescu, Yves Allory, Jacques Fieschi, Mathieu Rouanne, Florent Ginhoux, Gwénaël Le Teuff, Lisa Derosa, Aurélien Marabelle, Jeroen van Dorp, Nick van Dijk, Michiel S. van der Heijden, Benjamin Besse, Fabrice André, Miriam Mérad, Guido Kroemer, Jean‐Yves Scoazec, Laurence Zitvogel, Yohann Loriot

Cancer Discovery · 2022

Read source ↗ All evidence

Summary

In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli-specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies. This article is highlighted in the In This Issue feature, p. 2221.

Source type
Peer-reviewed study
DOI
10.1158/2159-8290.cd-22-0201
Catalogue ID
BFmoef2rp2-1fqck1
Pulse AI · ask about this record

Dig deeper with Pulse AI.

Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.